473 related articles for article (PubMed ID: 33475317)
21. Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas.
Chen L; Zhang H; Lu J; Thung K; Aibaidula A; Liu L; Chen S; Jin L; Wu J; Wang Q; Zhou L; Shen D
IEEE Trans Med Imaging; 2018 Aug; 37(8):1775-1787. PubMed ID: 29994582
[TBL] [Abstract][Full Text] [Related]
22. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
[TBL] [Abstract][Full Text] [Related]
23. MRI-Based Deep-Learning Method for Determining Glioma
Yogananda CGB; Shah BR; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
AJNR Am J Neuroradiol; 2021 May; 42(5):845-852. PubMed ID: 33664111
[TBL] [Abstract][Full Text] [Related]
24. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
25. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
26. Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Regnery S; Behl NGR; Platt T; Weinfurtner N; Windisch P; Deike-Hofmann K; Sahm F; Bendszus M; Debus J; Ladd ME; Schlemmer HP; Rieken S; Adeberg S; Paech D
Neuroimage Clin; 2020; 28():102427. PubMed ID: 33002860
[TBL] [Abstract][Full Text] [Related]
27. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
[TBL] [Abstract][Full Text] [Related]
28. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.
Bahrami N; Hartman SJ; Chang YH; Delfanti R; White NS; Karunamuni R; Seibert TM; Dale AM; Hattangadi-Gluth JA; Piccioni D; Farid N; McDonald CR
J Neurooncol; 2018 Sep; 139(3):633-642. PubMed ID: 29860714
[TBL] [Abstract][Full Text] [Related]
29. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive Assessment of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space-Occupancy Combined with Structural Magnetic Resonance Imaging.
He W; Li X; Hua J; Liao S; Guo L; Xiao X; Liu X; Zhou J; Wang W; Xu Y; Wu Y
J Magn Reson Imaging; 2021 Jul; 54(1):227-236. PubMed ID: 33590929
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
[TBL] [Abstract][Full Text] [Related]
33. IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas.
Kramář F; Minárik M; Benešová L; Halková T; Netuka D; Bradáč O; Beneš V
Folia Biol (Praha); 2016; 62(5):194-202. PubMed ID: 27978414
[TBL] [Abstract][Full Text] [Related]
34. Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion.
Kanazawa T; Minami Y; Takahashi H; Fujiwara H; Toda M; Jinzaki M; Yoshida K; Sasaki H
Neurosurg Rev; 2020 Aug; 43(4):1211-1219. PubMed ID: 31402410
[TBL] [Abstract][Full Text] [Related]
35. The Value of Enhanced MR Radiomics in Estimating the IDH1 Genotype in High-Grade Gliomas.
Niu L; Feng WH; Duan CF; Liu YC; Liu JH; Liu XJ
Biomed Res Int; 2020; 2020():4630218. PubMed ID: 33163535
[TBL] [Abstract][Full Text] [Related]
36. Applications of radiomics and machine learning for radiotherapy of malignant brain tumors.
Kocher M; Ruge MI; Galldiks N; Lohmann P
Strahlenther Onkol; 2020 Oct; 196(10):856-867. PubMed ID: 32394100
[TBL] [Abstract][Full Text] [Related]
37. Editorial for "Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma".
Salihoğlu AK; Booth TC
J Magn Reson Imaging; 2023 Sep; 58(3):739-740. PubMed ID: 36594487
[No Abstract] [Full Text] [Related]
38. The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis.
Zhou M; Niu C; Jia L; He H
Medicine (Baltimore); 2019 Dec; 98(50):e18194. PubMed ID: 31852075
[TBL] [Abstract][Full Text] [Related]
39. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
40. Radiomics for predicting MGMT status in cerebral glioblastoma: comparison of different MRI sequences.
Zheng F; Zhang L; Chen H; Zang Y; Chen X; Li Y
J Radiat Res; 2024 May; 65(3):350-359. PubMed ID: 38650477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
